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A B S T R A C T
As a consequence of the current excellent loco-regional control rates attained using the generally accepted
treatment paradigms involving intensity-modulated radiotherapy for nasopharyngeal carcinoma (NPC), only
10–20% of patients will suffer from local and/or nodal recurrence after primary treatment. Early detection of
recurrence is important as localized recurrent disease is still potentially salvageable, but this treatment often
incurs a high risk of major toxicities. Due to the possibility of radio-resistance of tumors which persist or recur
despite adequate prior irradiation and the limited tolerance of adjacent normal tissues to sustain further addi-
tional treatment, the management of local failures remains one of the greatest challenges in this disease. Both
surgical approaches for radical resection and specialized re-irradiation modalities have been explored.
Unfortunately, available data are based on retrospective studies, and the majority of them are based on a small
number of patients or relatively short follow-up. In this article, we will review the different salvage treatment
options and associated prognostic factors for each of them. We will also propose a treatment algorithm based on
the latest available evidence and discuss the future directions of treatment for locally recurrent NPC.
Introduction
The previous review by the International Head and Neck Scientific
Group (IHNSG) on recurrent nasopharyngeal carcinoma (NPC) sum-
marized the available data that had emerged over the past decade prior
to 2010 to identify the scope of the problem [1]. With the adoption of
intensity-modulated radiotherapy (IMRT)± stereotactic radiotherapy
(SRT) for the primary management of NPC in the contemporary era, a
renewed review of strategies is needed for the management of recurrent
NPC as most failures are now likely to be related to radioresistance.
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Furthermore, most of the adjacent normal tissues have already endured
varying degrees of damage from the previous course of high-dose
radiotherapy (RT). This poses additional complexity and challenges in
the salvage treatment. In this article, we will focus on the different
salvage options reported in the recent decade and their associated
prognostic factors. A treatment algorithm based on the latest evidence
is proposed and we will also explore the various ways of the future
direction of various approaches that might be useful in tackling this
challenging condition.
Scope of the problem
Using IMRT in the primary setting, excellent loco-regional control
rates have been consistently achieved in the treatment of NPC [2,3]. A
study by the Hong Kong Nasopharyngeal Cancer Study Group
(HKNPCSG-1301 study) recently reported eight-year survival outcomes
for NPC patients receiving primary treatment by IMRT with/without
chemotherapy at public oncology centers in Hong Kong [4]. Amongst
the 3328 patients included, 14% of them developed local recurrence or
persistent disease, while 21% had concomitant distant metastasis at the
time of local relapse. The median time from the diagnosis of primary
NPC to local recurrence was approximately 30months. Among the
patients with recurrence, 41% had local recurrence detected within the
first two years, 44% in the second to fifth year and 15% of the re-
currences were detected more than five years later.
The majority of the local recurrences were noted to be in the high
dose zone [5,6]; while marginal failure (≤2.1%) and geographical miss
(0–1%) were uncommon. Hence, it is obvious that most of the re-
currences result from radio-resistance [7]. In addition, these radiation
resistant tumors are surrounded by critical organs at risk (OAR) that
have already absorbed near tolerance radiation dose.
Detection of local recurrence
Vigilant follow-up by physical and endoscopic examination, sur-
veillance monitoring by magnetic resonance imaging (MRI) and de-
termination of plasma Epstein-Barr virus deoxyribonucleic acid (EBV
DNA) level at regular intervals are recommended for all NPC patients
following primary treatment. As subsequently illustrated in this
manuscript, the importance of early detection cannot be over-empha-
sized as this is associated not only with a higher chance of survival, but
also with better salvage options with lower toxicities.
Endoscopy
Periodic endoscopic examination is the one of the main modalities
for follow-up assessment [8]. The emerging development of narrow-
band imaging endoscopy offers a diagnostic advantage. Wang et al.
reported that narrow-band imaging endoscopy could enhance the de-
tection rate of mucosal recurrent lesions (88% for both sensitivity and
specificity) [9], and also noted that post-radiation effects may give rise
to false-positive results. However, neither method could detect deep
seated or skull base recurrence.
MRI
MRI is another main modality for follow-up assessment, but inter-
pretation still remains challenging [10]. Both recurrent tumor and post-
therapeutic inflammatory changes may display hyperintensity with
intense enhancement on T2-weighted (T2W) images on conventional
MRI, leading to equivocal distinction between the two differential di-
agnoses [11]. Similarly, post-RT induced scar tissue and bony changes
also pose diagnostic difficulty in differentiating from the highly variable
appearance of recurrent tumors [12]. Diffusion-weighted imaging is
now increasingly used as distinction can be improved by the differences
in intravoxel incoherent motion-diffusion and perfusion morphology
patterns [13,14].
Positron emission tomography-computed tomography (PET-CT)
PET-CT at the time of local recurrence is valuable as up to ~20% of
patients have been reported to have concomitant distant metastasis at
the time of local recurrence [15,16]. Furthermore, Yen et al. reported
that FDG-PET was superior to MRI in detecting residual/recurrent NPC,
showing improvement in sensitivity (100% vs. 62%), specificity (93%
vs. 44%) and accuracy (96% vs. 49%) [17].
Another recent meta-analysis revealed that both PET-CT and single-
photon emission computed tomography (SPECT) facilitated accurate
detection of residual/locally recurrent NPC. Superiority to MRI in the
distinction between recurrent disease versus post-RT changes was de-
monstrated: the pooled specificity estimates for PET-CT (93%) and
SPECT (81%) were higher than for MRI (76%) [18]. However, it should
be noted that PET-CT may give false-positive results arising from post-
RT mucosal inflammatory changes/mucositis or osteonecrosis.
EBV DNA
Despite the lack of prospective data and the need of standardization
of the test, monitoring of plasma EBV DNA is found to be useful for
follow-up assessment, especially for the detection of distant failures
[19,20]. However, its sensitivity in the detection of local recurrences is
relatively low. Elevated plasma EBV DNA level was seen in 55% to 96%
of patients with distant metastases, but varied from 0% to 67% in pa-
tients with local and/or nodal recurrence [20–24]. Nonetheless, plasma
EBV DNA level is still useful, as a high pre-operative level may identify
those at a higher risk of distant failure after attempt at salvage surgery
[25].
The use of trans-oral nasopharyngeal brush biopsy for EBV DNA in
the detection of local NPC recurrence has also been reported [26]. In a
series by Hao et al., nasopharyngeal swab testing for PCR-based latent
membrane protein (LMP)-1 gene and Epstein-Barr nuclear antigen
(EBNA)-1 gene was used to monitor local recurrence in 84 NPC patients
[27]. Of the 12 patients who were tested positive for both LMP1 and
EBNA1, 11 developed local recurrence (sensitivity 91.7%, specificity
98.6%). This method is convenient and simple but its reliability for
detecting deep-seated lesions may be limited.
Surgical approach
There is as yet no randomized controlled trial offering a head to
head comparison of surgery versus re-irradiation or systemic therapy in
the management of recurrent NPC. Retrospective comparisons are
hindered by various confounding factors: eligible surgical candidates
usually exhibit more clinically favorable profiles with lower disease
volume, earlier r-T category, better performance status and fewer
medical co-morbidities.
Retrospective studies have suggested that the local salvage rates
were similar between surgery and re-irradiation [28], but a recent case-
matched study by You et al. demonstrated that endoscopic nasophar-
yngectomy offered more optimal treatment outcomes, better quality of
life (QOL) and a significantly lower rate of treatment-related compli-
cations as compared with salvage IMRT [29].
In view of the high incidence of severe late toxicities associated with
re-irradiation [30], surgical salvage should be considered in resectable
cases. Various surgical techniques (including endoscopic resection±
robotic assistance [31] and open nasopharyngectomy via various ap-
proaches [32]) could be adopted depending on the disease extent and
location.
The resectability of the recurrent diseases can be broadly categor-
ized as follows:
– Easily resectable: rT1 disease, rT2–3 with limited parapharyngeal
space involvement or disease confined to the base of sphenoid sinus.
– Potentially resectable (definition could vary depending on avail-
ability of expertise) [33]: involvement of the internal carotid artery
(ICA), limited invasion to the clivus, posterior maxillary sinus,
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pterygoid process and petrous apex.
– Unresectable: tumor invading both cortexes of the clivus (difficult to
repair the dura in a water-tight manner if inadvertently damaged),
significant involvement of the lateral wall of the sphenoid sinus (due
to the presence of internal carotid artery, optic nerve and abducens
nerve), frank cavernous sinus or intracranial invasion, and multiple
areas of skull base involvement [33].
The advantages and disadvantages of open surgery vs. endoscopic
resection for early resectable recurrences are delineated in the Table 1.
Irrespective of the operative approach, exposed ICA, bone and dura
should be covered by a muscle flap. One approach is to use the vastus
lateralis muscle free flap tunneled medial to the body of the mandible to
the neck, where a microvascular anastomosis will be carried out [34].
Special surgical techniques are also needed for recurrent disease
with carotid artery involvement. A two-stage operation has been de-
scribed: an extra-to-intracranial vascular bypass using the autologous
radial artery or long saphenous vein is performed during the first-stage.
After ascertaining the patency of the bypass by CT angiogram, the
tumor including the involved bone and ICA will be removed en-bloc in
the second operation [35].
The treatment outcomes of open surgery and endoscopic resection
are summarized in Table 2 [36–46]. Irrespective of treatment methods,
local control exceeding 50% has been consistently reported in modern
series. Peri-operative mortality rate seems low and late complications
appear to be significantly less common than after re-irradiation, parti-
cularly if an endoscopic approach has been used. Furthermore, global
quality of life (QOL) after salvage nasopharyngectomy has been re-
ported as generally good; only palatal fistula and osteoradionecrosis
might potentially affect the social life of the patients [47]. The results of
removal of recurrent nasopharyngeal carcinomas after radiotherapy
failure are encouraging for rT1–T2 and select T3 tumors, and even for
T4 tumors with extracranial extension. On the other hand, patients with
rT4 tumors with intracranial involvement generally recur locally or die
due to development of metastatic disease. Although some authors re-
port encouraging results in the case of intracavernous involvement,
surgical salvage of NPC recurrence with significant intracranial exten-
sion is usually not justified.
While the role of surgical treatment is increasingly recognized if
expertise is available, the role of adjunctive RT and/or chemotherapy
remains unclear, except that most would agree to consider post-op-
erative RT for patients with positive resection margins [48].
Re-irradiation approach
Various studies conducted in recent years have advocated IMRT,
SRT or intensity-modulated proton therapy (IMPT) for re-irradiation.
These techniques have surpassed the roles of brachytherapy, 3D-con-
formal RT and other older techniques [1]. Various radiobiological
factors including total dose, dose/fraction, altered fractionation, dose
tolerance of OAR (especially the nasopharyngeal mucosa, carotid ves-
sels and neurological structures) and their prior dose exposure should
be carefully considered. Furthermore, the best quality control of RT
technique and precision set-up should be adopted for maximal sparing
of the neighboring uninvolved normal tissues.
IMRT is universally the most used modality at present, and most
protocols aim to deliver a radiation dose of ≥60 Gy to the recurrent
gross tumor volume (rGTV), to achieve a promising local control rate of
52–86% [49–55]. Table 3 summarizes the recent studies based on IMRT
[7,16,49–51,53–61] and provides an in-depth analysis of the effect of
re-irradiation on overall survival. Such studies can be broadly divided
into two groups based on the reirradiation dose (≤60 Gy vs.> 60 Gy).
The reported five-year survival rates range from 28 to 60%, with
rT3–T4 disease at the lower end of the survival spectrum. Fatal
Table 1
Comparison between open surgery and endoscopic resection.
Open surgery Endoscopic resection
Advantages Better macroscopic exposure to the operating field
Most suitable for more locally advanced tumors close to internal
carotid artery
Less invasive
Avoids the morbidities inherent with open procedure
Most suitable for centrally located tumors, especially rT1–T2 with limited
parapharyngeal involvement
Procedure-specific complications Cosmesis, facial numbness, trismus, palatal fistula formation,
nasal blockage, ectropion, epiphora
Flap necrosis with flap coverage of the NP defect
Other complications in common Skull base osteonecrosis, inadvertent damage to the carotid vessel, velopharyngeal insufficiency, eustachian tube dysfunction causing otitis media
with effusion
Table 2
Efficacy and major complications of selected series of nasopharyngectomy for recurrent nasopharyngeal carcinoma.
Author No. rT1 (%) Post-operative RT (%) Salvage rate (5 year) Severe complications
LC (%) OS (%) Carotid injury/Massive bleeding (acute or late) (%) Hospital mortality (%)
Open surgery
King et al. [36] 31 65 77 43 47 3 0
Fee et al. [37] 37 59 22 67 60 3 3
Hao et al. [38] 53 51 39 54 49 4 0
Vlantis et al. [39] 97 55 73 47 52 3 0
Wei et al. [40] 246 NS NS 74 56 1 0
Bian et al. [41] 71 38 NS 54 42 0 0
Ng et al. [42] 20 90 NS 70 67 0 0
Endoscopic surgery
Chen et al. [43] 37 46 0 86* 84* 0 0
Ko et al. [44] 28 43 7 T1−100*
T2−42*
59* 4 0
Zou et al. [45] 92 50 NS NS 78 NS NS
Liu et al. [46] 91 33 NS NS 38 10 0
Abbreviation: LC – local control, NS – not stated, OS – overall survival.
* 2 year outcomes.
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complications are not uncommon, especially in series delivering a high
total dose (≥70 Gy) for the second course of RT. The commonest cat-
astrophic toxicities include carotid blowout, temporal lobe necrosis,
mucosal necrosis and aspiration pneumonia. Given the narrow ther-
apeutic margin, it is important to note that a higher radiation dose may
not lead to higher chance of survival as fatal complications negate the
benefit of higher tumor control rates.
Due attention should also be paid to the allowable maximal toler-
ated dose for neurologic OARs in the second course of radiotherapy.
Several models have been proposed based on the partial recovery from
the first course of treatment by approximately 50% (provided that the
first course was delivered more than 1 year ago) [62,63], total
cumulative radiation dose [64,65] and the time interval between the
two courses of radiotherapy [66,67]. However, all of these models are
based on rather scanty clinical information, and details of dose dis-
tribution within the OARs are largely unknown. Hence the OARs tol-
erance in the second course of treatment should always be guided by
the “As Low As Reasonably Practicable” principles. Similar considera-
tion also apply to the design of re-irradiation volume, and elective
treatment (such as the uninvolved regional nodal basin or the sub-
clinical disease in the vicinity of rGTV) is generally not recommended
as reported in other locally recurrent head-and-neck squamous cell
carcinoma (SCCHN) [68], and the treatment targets usually consist of
the rGTV with tight margin only.
Table 3
Cross-study comparisons for selected series of recurrent nasopharyngeal carcinoma treated with intensity modulated radiotherapy.
Author No. of
patients
% rT3–4 Dose (Gy) Median
FU
(months)
Endpoint
(year)
Local control
(%)
OS
(%)
Severe complications
(%)
Fatal complication (%)
Planned total radiation dose > 60 Gy
Qiu et al. [51] 70 57 50–77.4
(median 70)
25 3 49
(LRRFS)
52 mucosal necrosis – 16
CN palsy – 24
TLN – NR
massive epistaxis – 9
massive epistaxis – 9
Han et al. [49] 239 75 61.7–78.7
(mean 69.9)
29 5 86
(LRFS)
45 mucosal necrosis – 41
brain injury – 29
overall – 35
Chen et al. [54] 54 80 49.8–76.6
(mean 70)
17 2 64
(LPFS)
44 mucosal necrosis – 32
dysphagia – 20
TLN – 19
massive epistaxis – 11
overall – 25
Hua et al. [50] 151 81 62.1–77.6
(mean 70.4)
40 3 83
(LCR)
46 mucosal necrosis – 20
CN palsy – 13
brain injury – 22
massive epistaxis – 19
brain injury – 17
Tian et al. [55] 117 79 65.4–73.1 25 3 64-71b
(LFFS)
48 mucosal necrosis – 39
CN palsy – 13
TLN – 21
overall – 32 including
mucosal necrosis / bleeding –
20
TLN – 4
Tian et al. [56] 245 100 60.1–78.7
(median 70)
24 5 61
(LRFFS)
28 mucosal necrosis – 27
CN palsy – 14
TLN – 22
massive epistaxis – 16
overall – 29 including
mucosal necrosis / bleeding –
13
TLN – 7
Kong et al. [7] 77 39 46.2–70
(median 66)
26 3 67
(LPFS)
52 mucosal necrosis – 40
CN palsy – 26
TLN – 9
overall – 53 including
mucosal necrosis / bleeding –
22
Kong et al. [57] 184 65 42–77
(median 66.7)
33 3 85
(LRFS)
46 mucosal necrosis – 30
CN palsy – 11
mucosal necrosis – 24
Planned total radiation dose ≤60 Gy
Chua et al. [53] 31 75 50-60a
(median 54)
11 1 65
(LPFS)
63 CN palsy – 10
brain necrosis – 7
NR
Koutcher et al. e
[58]
29 45 (median
45–59.4)a
45 5 52
(LCR)
60 CN palsy – 7
TLN – 14
NR
Karam et al. [59] 27 23 44–59.4
(mean 51)
36 3 53
(LCR)
[49]c mucosal necrosis – 0
CN palsy – 7
TLN − 0
0
Chan et al. [16] 38 100 50–64.8d 48 3 44
(LCR)
47 mucosal necrosis – 23
TLN – 24
dysphagia – 24
massive epistaxis −
20
massive epistaxis – 8
Lee et al. [60] 20 100 60–64.8d 45 3 [<26%]c
(LFFS)
[35]c brain necrosis – 20
aspiration – 30
massive epistaxis – 15
massive epistaxis – 15
Ng et al. [61] 32 100 60 29 3 45
(LCR)
64 mucosal necrosis – 15
TLN – 31
CN palsy – 31
dysphagia – 15
massive epistaxis – 12
massive epistaxis – 8
TLN – 1
Abbreviations: LCR – local control rate, LFFS – local failure free survival, LPFS – local progression free survival, LRFFS – locoregional failure free survival, LRFS –
local recurrence free survival, LRRFS – locoregional recurrence free survival, NR – not reported, OS – overall survival.
a Some patients had additional stereotactic radiotherapy or brachytherapy boosting.
b 5 year.
c Estimated figure.
d 1.2 Gy per fraction, twice daily.
e 83% IMRT.
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Another commonly employed precision treatment technique for
locally recurrent NPC is SRT. Table 4 summarizes the published series
reported since our last review [1,69–73]. The number of patients
treated with this technique is too small for robust comparisons with
IMRT [69–75]. This is still considered a technical approach that re-
mains under development.
The availability of IMPT in recent years, a technique which is
characterized by its unique beam properties of a Bragg peak followed
by a rapid distal fall-off, has optimized the physical dose distribution
and OAR sparing [76]. A study by Lin et al. [77], using IMPT to doses of
59.4–70.2 cobalt gray equivalent in 16 patients with recurrent NPC (12
of whom had rT4 disease), reported 50% OS and loco-regional PFS at
2 years, with low doses (0–22 Gy) given to the critical OARs resulting in
minimal side effects to central nervous system structures. On the other
hand, Feehan et al., using heavy charged particles to a median dose of
50 Gy equivalent in 11 patients with recurrent T3–4 NPC, reported less
remarkable results [78]: at a median follow up of 28months, the local
control rate was 45%, but temporal lobe necrosis (TLN) and serious
aneurysmal bleeding were observed in 36% and 9% of patients, re-
spectively. No long-term outcomes and side effects were subsequently
reported for these two series. The study by Hu et al., using carbon ions
to doses of 50–66 Gy equivalent in 75 patients with recurrent NPC [79],
reported an encouraging 87% local recurrence-free survival at one year,
but the median follow-up was only 15months and longer observation
seems warranted. Furthermore, mucosal necrosis and TLN were ob-
served in 9.3% and 1.3% of patients respectively, demonstrating that
the NP mucosa will be a key dose limiting factor with particle beam
therapy.
One of the most important considerations associated with re-irra-
diation is the risk and the severity of RT-related toxicities. According to
a recent meta-analysis [30], grade 5 toxicities were observed in 33% of
patients, with the most common severe effects being mucosal necrosis
and massive hemorrhage, followed by feeding difficulties and radiation
encephalopathy [30,56].
Carotid blowout is one of the major causes of treatment-related
deaths. A literature-based systematic review by McDonald et al. on
1554 patients reported a crude incidence rate of 2.6% following re-
irradiation to the head and neck region, and the mortality rate was 76%
[80]. The reported rate of hemorrhage after re-irradiation for NPC has
varied widely: the incidence after IMRT or SRT ranges from 0 to 25%.
[54,70,71,81] Apart from the dose to the carotid artery [82], the total
re-irradiation dose is also an important factor. In a phase 2 randomized
study by Tian et al. in which two IMRT dose regimens in recurrent NPC
were compared [55], the massive hemorrhage rate at a median follow-
up of 25months was 19% in the group given 60 Gy in 27 fractions as
compared with 31% in the group given 68 Gy in 34 fractions; the prior
radiotherapy dose was the same in the two groups.
Mucosal and adjacent soft tissue/bone necrosis is frequently ob-
served after re-irradiation, causing foul odor, intense headache, and/or
profuse bleeding. Endoscopic examination showed extensive areas of
crusting, necrotic tissue and even exposed bone. This can also give rise
to massive nasal bleeding similar to the carotid blowout syndrome. The
reported incidence ranged from 6.3% to 40.6% [49,51,54,55]. In the
study reported by Yu et al. on 204 patients [83], lethal nasopharyngeal
necrosis (LNN) was observed in 31 patients (15.2%). Logistic regression
analysis revealed several independent risk factors for LNN: including
the female sex, presence of necrosis before re-irradiation, accumulated
total prescription dose to GTV≥ 145.5 Gy, and recurrent tumor volume
≥25.38 cm3. A curative-intent endoscopic necrectomy followed by re-
construction using the posterior pedicle nasal septum and floor muco-
periosteum flap was recently described as a safe and effective treatment
for post-radiation nasopharyngeal necrosis [84].
Dysphagia is another common RT-related toxicity. The cause of
dysphagia can be related to trismus, pharyngeal constrictor muscle
dysfunction and/or cranial nerve (IX-XII) injury. Chen et al. reported
that 20% of patients required long term feeding tube insertion or gas-
trostomy due to severe dysphagia after re-irradiation [54]. Other series
have reported severe trismus rates of around 15% [51,55,58].
Last but not least, TLN is another serious late toxicity that is po-
tentially life-threatening. While some patients may be asymptomatic
especially at the early stage, others progressively develop debilitating
symptoms including headache, dizziness, memory loss, epilepsy, pres-
sure symptoms, changes in consciousness and/or occasional in-
tracranial hemorrhage [85]. The incidence of TLN is much higher in the
re-irradiation cohort than that of single-course RT, ranging from 7% to
35%. [49,53–55,58,86] Risk factors for TLN include the fractional dose,
the cumulative dose, the technique of RT and the time interval between
the 2 RT courses [87–90]. The study by Liu et al. on over 200 recurrent
NPC patients re-irradiated to around 70 Gy revealed a 31% risk of TLN
with a median latency period of only 15months [91]; a maximum cu-
mulative dose of less than 125 Gy (calculated as equivalent dose in 2 Gy
fractions (EQD2)) and an intervening treatment interval of at least
2 years from prior radiation were recommended.
Role of systemic treatment
Despite the lack of high-level evidence, induction and/or concurrent
chemotherapy is often given with re-irradiation. Induction che-
motherapy is especially considered in patients with rT3–4 diseases
because this may down-size the recurrent tumor bulk facilitating easier
Table 4
Recent reports on stereotactic radiotherapy for recurrent nasopharyngeal carcinoma.
Author No. of patients % rT3–4 Dose Median
FU
(months)
Endpoint (year) Local control
(%)
OS
(%)
Severe complications Fatal complication
Dizman et al. [69] 24* 42% 5–6 Gy/fr, 5 fr 20 3 21 31 4% TLN 4%
Ozyigit et al. [70] 24 71% 6 Gy/fr, 5 fr 23 2 82 NR 12% cranial neuropathies,
4% TLN,
17% carotid blowout
12.5%
Seo et al. [71] 35** 43% 7.5–12 Gy/fr, 3–5 fr 25 5 79 60 6% mucosal necrosis,
9% NP hemorrhage
6%
Leung et al. [72] 30 30% 2.5–4.5 Gy/fr, 8–22 fr 47 5 57 40 23% cranial neuropathies,
20% TLN
3%
Chua et al. [73] 43*** 30% 8–18 Gy in single fr 40 3 51 66 16% brain necrosis
2% NP hemorrhage
0%
43*** 30% 20–49 Gy in 4–6 fr 24 3 83 61 12% brain necrosis
4% NP hemorrhage
7%
Abbreviations: fr – fraction, NP – nasopharyngeal, TLN – temporal lobe necrosis.
* 29% had metastatic disease.
** 9% – no records for the evaluation of the toxicity data.
*** 44% – persistent disease.
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sparing of adjacent OARs and eradicate micro-metastases. Concurrent
chemotherapy may improve radio-sensitivity leading to improved local
tumor control. However, the potential aggravating effect of che-
motherapy related to increased late toxicities should also be addressed.
It is also unclear whether chemotherapy can be safely sequenced or
combined with stereotactic or other hypofractionated or accelerated
forms of re-irradiation.
Various chemotherapy agents and their combinations have been
investigated in the locally recurrent setting, including cisplatin [58,92],
5-fluorouracil [92], gemcitabine [93] and taxanes [61]. Targeted
agents such as anti-epidermal growth factor receptor agents [61,94]
have also been tried, though no study has been reported with anti-an-
giogenic agents due to the underlying risk of hemorrhagic complica-
tions for locally recurrent tumors. In fact, in the study reported by Hui
et al. on thirteen NPC patients who were treated with sunitinib and had
previously been given high-dose radiation to upper aerodigestive tract,
a high incidence (64%) of hemorrhagic events was found, and it ap-
peared that direct vascular invasion by tumors (which is not uncommon
in the locally recurrent setting) further increased the risk of serious
bleeding [95]. Hence, the study of anti-angiogenic agents is now mainly
confined to use in the distant metastatic setting [96]. On the other
hand, the HKNPCSG has reported a study aiming to evaluate the effect
of induction docetaxel, cisplatin, and fluorouracil (TPF) followed by
weekly docetaxel and cetuximab given concurrently with IMRT on the
overall treatment outcomes among a group of rT3–4 patients without
distant metastasis. While the proposed regimen achieved a superior
treatment outcome (3-year PFS and OS rates of 36% and 64%, re-
spectively) compared with results seen in previous studies, the poor
tolerability of induction TPF and the high rate of TLN (31%) will im-
pose limitations on its applicability [61].
Another proposed approach suggests treatment of advanced re-
current disease with chemotherapy alone [97]. A case-control study on
88 rT3–4 N0-1 NPC patients treated with chemotherapy with or without
re-RT reported no statistical significance in the 5-year survival rates
between the two groups (27.5% vs 23.4%), suggesting the possibility of
sole use of chemotherapy in conservative settings.
No ongoing studies focus on the emerging role of immunotherapy in
locally recurrent NPC. Promising results have been reported with
pembrolizumab, nivolumab, and camrelizumab in the second-line set-
ting (overall response rate 20–34%) [98–100] or in combination with
chemotherapy (overall response rate 91%) [100]. However, all of these
studies comprise small series of mixed groups with distant metastases
and/or local-regional recurrence. Therefore, the exact role of im-
munotherapy in the management of locally recurrent NPC remains yet
to be evaluated. The observed long-term disease control in some pa-
tients with recurrent or metastatic SCCHN [101,102] warrants in-
vestigation of immunotherapy as a single modality or in combination
with radiation therapy in the treatment of locally recurrent disease.
Studies are currently combining re-irradiation with immune check
point inhibitors in the treatment of recurrent SCCHN including NPC
(NCT03521570). Other novel strategies including adoptive im-
munotherapy [103] and therapeutic vaccine [104] are also under active
investigation.
Prognostic factors
Surgery
Several important adverse prognostic factors have been identified in
patients receiving surgery. These include advanced T category, large
tumor size, positive resection margins, presence of gross tumor in the
sphenoid sinus, cavernous sinus invasion and synchronous cervical
nodal metastasis [48,105]. Further modifications based on resectability
have been proposed regarding T category [106]. Specifically, resectable
rT2 and resectable rT3 were defined as tumor being confined to the
superficial parapharyngeal space, and tumor confined to the base of
sphenoid sinus.
A meta-analysis in 2014 involving 779 patients with locally re-
current NPC showed that endoscopic surgery was superior to open
surgery in selected patients with T3/4 disease. In addition, this study
showed that adjuvant re-irradiation achieved additional survival ad-
vantages when compared with surgery alone [48].
Radiotherapy
In a prognostic model proposed by Li et al. [107], five significant
prognostic factors for OS in patients with locally recurrent NPC were
identified: age, T-category of the recurrence (rT3–4), size of rGTV,
presence of prior RT-induced grade 3 or above toxicities, and the dose
of re-irradiation by IMRT (EQD2 of ≥68 Gy). A prognostic index (PI)
was constructed based on these five factors. A PI score of 252 con-
sistently categorizes patients into good vs poor risk for OS and grade
five toxicities. This may serve as a useful model to guide clinicians and
patients making decisions about re-irradiation. Table 5 summarizes
other factors that influence the outcomes of recurrent NPC as reported
by various studies [30,49,107–109]. Recurrent T category and tumor
size are the most consistent prognostic risk factors.
Treatment outcomes
The management strategy outlined above is the most commonly
adopted practice in Hong Kong, as shown in a recent Patterns of Care
study reported by the HKNPCSG [110]. The study included 272 locally
recurrent non-metastatic NPC patients who were treated with a primary
course of IMRT: their rT stage distribution was 30.5%, 9.6%, 25.4% and
34.6% for rT1, rT2, rT3 and rT4, respectively. Among these patients,
30.9% were treated with radical surgery± adjuvant RT or che-
motherapy, 35.7% with re-RT± induction or concurrent che-
motherapy, 23.2% with palliative chemotherapy alone, and 10.3%
were managed with palliative intent with no active treatment given.
Table 5
Adverse prognostic factors affecting the outcomes of recurrent nasopharyngeal carcinoma after re-irradiation.
Han et al. [49] Li et al. [107] Leong et al. [30]* Tian et al. [108] Yue et al. [109]
Gender NR NR NR NR No association
Age Age > 46 Increasing age NR Age > 50 No association
Performance status NR NR NR KPS≤ 70 NR
Time to recur NR NR <36months NR No association
rT category Increasing rT rT3–4 rT3–4 rT3–4 Increasing rT
rGTV >38 cc Increasing rGTV NR >30 cc Increasing rGTV
rN+ rN+ NR High nodal burden rN+ No association
2nd course RT dose NR ≥68 Gy NR NR No association
Mean fractional dose < 2.3 Gy NR NR NR NR
Prior RT complications NR Presence of≥G3 toxicities NR Presence of late complications NR
Addition of chemotherapy NR NR No association NR No association
Abbreviations: GTV – gross tumor volume, KPS – Karnofsky performance status, NR – not reported, RT – radiotherapy.
* Reirradiaton dose≥ 70 Gy to rGTV was not associated with improved survival.
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The most common treatment modality for recurrent stage I, II, III and IV
diseases was surgery (82.3%), surgery (38.1%) or re-RT (38.1%), re-RT
(52.1%), and chemotherapy alone (42.3%), respectively. The 5-year OS
for the whole series was 30.2%, and the corresponding 5-year OS for
patients who received surgery, re-RT, chemotherapy or no active
treatment was 56.3%, 21.8%, 11.6% and 11.1%, respectively. Our re-
sults indicate favorable long-term outcomes with surgery for a re-
sectable recurrence, while re-RT will achieve a two-fold OS improve-
ment compared against chemotherapy or no active treatment.
Treatment algorithm and follow up
The appropriate treatment algorithm for patients with locally re-
current NPC is described in detail in Fig. 1. Multidisciplinary assess-
ment with comprehensive consideration of all factors (including re-
current tumor factors, prior treatment factors and patient factors), and
an in-depth discussion with the affected patient are important for
treatment decisions. Salvage surgery should be considered whenever
feasible, while re-irradiation should be considered for patients with
unresectable disease, or those who are unsuitable or reluctant for sur-
gery. For patients with extensive recurrences, it is impossible to attain
adequate therapeutic dose coverage using re-irradiation due to the
limited remaining tolerance of critical OARs; treatment by che-
motherapy and/or immunotherapy is an alternative option.
After radical salvage treatment, follow-up is similar to that re-
commended by the NCCN [111] and ESMO [8] guidelines as in the
setting of primary treatment. This consists of a combination of periodic
clinical and radiological assessment. Clinical examination of the
nasopharynx and neck, cranial nerve function, fiberoptic endoscopy,
and evaluation for the presence of systemic symptoms are performed at
approximately every 3months in the first 2 years, half-yearly at
3–5 years after treatment, and annually thereafter. MRI should also be
performed every 6–12months not only for surveillance of the local
disease but also the detection of late complications. Patients are also
regularly reviewed by nurse specialists and relevant allied health pro-
fessionals for supportive care, rehabilitation of speech, hearing, swal-
lowing function, and monitoring of nutritional status.
Future directions
Recent advances in robotic surgery and 3D-endoscopic visualization
have enhanced surgical feasibility and accessibility. The Da Vinci ro-
botic surgical system provides a magnified, three-dimensional view of
the surgical field, and thus facilitates more precise surgical dissection
with the possibility of three-handed manipulation. The next-generation
flexible robotic surgical systems further improve the access to the na-
sopharynx, avoiding the need to split the soft palate and enabling si-
multaneous manipulation of four instruments (three surgical instru-
ments and a camera) into the NP without collision or restriction of the
surgeons’ joint movement [112]. Furthermore, anecdotal series on
photodynamic therapy suggest that this form of treatment may also
play a role in the salvage of superficial NP recurrence [113–115].
Integration of RT with immunotherapy has been proposed with
promising preclinical data of radiosensitization by immune checkpoint
blockade therapies [116]. The newly launched HKNPCSG trial will
examine this concept in further scope, by combining re-irradiation with
Fig. 1. Treatment algorithm for locally recurrent nasopharyngeal carcinoma. Abbreviations: EBV DNA – Epstein-Barr virus deoxyribonucleic acid, OARs – organs at
risk, PET – positron emission tomography, PS – performance status, QOL – quality of life.
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avelumab for unresectable localized recurrent NPC. Better under-
standing of the tolerance of key OARs is obviously important for opti-
mizing dose-fractionation schedules for re-irradiation. Previous pub-
lications by Yu et al. and IHNSG have provided useful summary data for
both mucosal [49] and carotid artery tolerances [117]. Photo-
biomodulation therapy using light therapy (lasers or LEDs) [118] has
shown promising potential to promote mucosal healing through bios-
timulation of cellular repair, angiogenesis, and its anti-inflammatory
effects. Preliminary evidence suggests that this can potentiate a clini-
cally effective treatment for post-irradiation mucosal necrosis. Other
strategies including hyperbaric oxygen [119] and tissue grafting [84]
have been described and further studies are warranted.
Conclusion
The evolution of the management of NPC has been very impressive.
High rates of local disease control have been achieved though both
technological improvements and oncological research. Paradoxically
this success has now made treatment of local recurrences extremely
challenging. This review summarizes the current clinical options, with
ongoing research targeting radioresistance and further technological
advances awaited.
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